Adriana H Tremoulet1, Sonia Jain2, Susan Kim3, Jane Newburger4, Moshe Arditi5, Alessandra Franco6, Brookie Best7, Jane C Burns8. 1. Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA. Electronic address: atremoulet@ucsd.edu. 2. Biostatistics Research Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 3. Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, USA. 4. Department of Cardiology, Harvard Medical School, Boston, MA, USA; Department of Pediatrics, Children's Hospital of Boston, Boston, MA, USA. 5. Department of Pediatrics, Cedars Sinai Medical Center, USA; UCLA School of Medicine, USA. 6. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. 7. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Skaggs School of Pharmacy, La Jolla, CA, USA. 8. Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA.
Abstract
BACKGROUND: Although Kawasaki disease (KD) is the most common cause of acquired heart disease in children and may result in coronary artery aneurysms (CAA) with an attendant risk of myocardial infarction, there is no recommended therapy to halt progression of arterial wall damage and prevent aneurysm formation in the acute phase of the vasculitis. While intravenous immunoglobulin (IVIG) reduces the risk of CAA, up to 20% of KD patients are IVIG resistant and have a higher risk for developing CAA. The IL-1 pro-inflammatory pathway is upregulated in children with acute KD and plays a critical role in the experimental animal model of KD. Thus, IL-1 is a logical therapeutic target. OBJECTIVES: The goal of this study is to determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of anakinra, a recombinant human IL-1 receptor antagonist, in acute KD patients with coronary artery abnormalities on the baseline echocardiogram. DESIGN: This is a two-center dose-escalation Phase I/IIa trial in 30 acute KD patients ≥8months old with a coronary artery Z score≥3.0 in the right coronary artery and/or left anterior descending artery or an aneurysm. Subjects will receive a 2- to 6-week course of anakinra by daily subcutaneous injection and will be assessed for resolution of inflammation and dose limiting toxicities (leukopenia, anaphylactoid reaction, or severe infection). CONCLUSION: The safety and tolerability of blocking both IL-1α and Il-1β by anakinra will be evaluated as a strategy to prevent or attenuate coronary artery damage in infants and children with acute KD. TRIAL REGISTRATION: Clinical Trials.gov # NCT02179853, registered June 28, 2014.
BACKGROUND: Although Kawasaki disease (KD) is the most common cause of acquired heart disease in children and may result in coronary artery aneurysms (CAA) with an attendant risk of myocardial infarction, there is no recommended therapy to halt progression of arterial wall damage and prevent aneurysm formation in the acute phase of the vasculitis. While intravenous immunoglobulin (IVIG) reduces the risk of CAA, up to 20% of KDpatients are IVIG resistant and have a higher risk for developing CAA. The IL-1 pro-inflammatory pathway is upregulated in children with acute KD and plays a critical role in the experimental animal model of KD. Thus, IL-1 is a logical therapeutic target. OBJECTIVES: The goal of this study is to determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of anakinra, a recombinant humanIL-1 receptor antagonist, in acute KDpatients with coronary artery abnormalities on the baseline echocardiogram. DESIGN: This is a two-center dose-escalation Phase I/IIa trial in 30 acute KDpatients ≥8months old with a coronary artery Z score≥3.0 in the right coronary artery and/or left anterior descending artery or an aneurysm. Subjects will receive a 2- to 6-week course of anakinra by daily subcutaneous injection and will be assessed for resolution of inflammation and dose limiting toxicities (leukopenia, anaphylactoid reaction, or severe infection). CONCLUSION: The safety and tolerability of blocking both IL-1α and Il-1β by anakinra will be evaluated as a strategy to prevent or attenuate coronary artery damage in infants and children with acute KD. TRIAL REGISTRATION: Clinical Trials.gov # NCT02179853, registered June 28, 2014.
Authors: Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky Journal: Arthritis Rheum Date: 2012-07
Authors: Sophie Cohen; Carline E Tacke; Bart Straver; Natasja Meijer; Irene M Kuipers; Taco W Kuijpers Journal: Ann Rheum Dis Date: 2012-06-11 Impact factor: 19.103
Authors: Antonia Fettelschoss; Magdalena Kistowska; Salomé LeibundGut-Landmann; Hans-Dietmar Beer; Pål Johansen; Gabriela Senti; Emmanuel Contassot; Martin F Bachmann; Lars E French; Annette Oxenius; Thomas M Kündig Journal: Proc Natl Acad Sci U S A Date: 2011-10-17 Impact factor: 11.205
Authors: S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff Journal: Crit Care Med Date: 1997-07 Impact factor: 7.598
Authors: Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe Journal: Arthritis Rheum Date: 2013-10
Authors: Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman Journal: Pediatrics Date: 2019-05-02 Impact factor: 7.124
Authors: M Abe; D D Rastelli; A C Gomez; E Cingolani; Y Lee; P R Soni; M C Fishbein; T J A Lehman; K Shimada; T R Crother; S Chen; M Noval Rivas; M Arditi Journal: Clin Exp Immunol Date: 2019-12-09 Impact factor: 4.330